SAB Biotherapeutics, Inc. revenue for the last year amounted to 2.23 M USD, the most of which — 2.24 M USD — came from its highest performing source at the moment, Immunotheraphies, the year earlier bringing 23.90 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought SAB Biotherapeutics, Inc. 2.24 M USD, and the year before that — 23.90 M USD.